6 Result(s)
within
Marjorie G. Zauderer
-
Article
Open AccessGenomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library
Diffuse pleural mesothelioma (DPM) is an aggressive malignancy that, despite recent treatment advances, has unacceptably poor outcomes. Therapeutic research in DPM is inhibited by a paucity of preclinical mode...
-
Article
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively foll...
-
Article
Open AccessPhase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1 dose escalation, 200 mg twice daily (BID) of LY3023414 was the determined recommended phase ...
-
Article
Open AccessThe therapeutic implications of the genomic analysis of malignant pleural mesothelioma
Delineation of the genomic complexities of malignant pleural mesothelioma (MPM) has lagged behind other malignancies. Zhang et al. meaningfully add to our understanding of MPM, and their findings emphasize the...
-
Article
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
Background Fibroblast growth factors (FGFs) have a fundamental role in cancer. Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small mo...
-
Chapter
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
Despite recent dramatic advances in many solid tumors, malignant mesothelioma remains challenging to treat. Historically, because of the modest number of cases globally and the substantial geographic distribut...
